Mayo Clinic Laboratory and Pathology Research Roundup: Feb. 26

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Blast Phase Myeloproliferative Neoplasm: Mayo-AGIMM Study of 410 Patients from Two Separate Cohorts

A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were retrospectively reviewed: 248 from Mayo Clinic and 162 from Italy. The median survival was 3.6 months, with no improvement over the last 15 years. Multivariable analysis performed on the Mayo cohort identified high-risk karyotype, platelet count, and transfusion need as independent risk factors for survival. Also in the Mayo cohort, intensive chemotherapy resulted in complete remission or complete remission with incomplete count recovery rates of 35% and 24%, respectively; treatment-specified 3-year/5-year survival rates were 32%/10% for patients receiving allogeneic stem-cell transplant, 19%/13% for patients achieving complete remission or complete remission with incomplete but were not transplanted, and 1%/1% in the absence of both allogeneic stem-cell transplant and complete remission or complete remission with incomplete. Similar observations were made in the Italian cohort. The current study identifies the setting for improved short-term survival in myeloproliferative neoplasm but also highlights the limited value of current therapy, including allogeneic stem-cell transplant, in securing long-term survival. The study was published in Leukemia.

Published to PubMed This Week

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.